• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

byConstance Wu
February 25, 2020
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

#StudyGraphics: Atezolizumab in combination with vemurafenib and cobimetinib improve progression-free survival in patients with BRAFV600-advanced melanoma

#VisualAbstract: Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma

Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma

1. Immune-related adverse events are associated with a longer recurrence-free survival in patients with stage III melanoma treated with pembrolizumab.

Evidence Rating Level: 1 (Excellent)

Immune-related adverse events (irAEs) occur frequently in patients treated with immune checkpoint inhibitors (ICIs). Retrospective studies and small prospective studies have reported an association between irAEs and improved outcomes in patients with melanoma and lung cancer, suggesting that irAEs may indicate increased drug activity. However, these associations require validation in larger prospective studies with adequate statistical methods. In this secondary analysis of a randomized controlled trial of 1,019 adults with stage III melanoma treated with either pembrolizumab or placebo, 1,011 patients commenced treatment and were studied to investigate the association between irAEs and recurrence-free survival (RFS). At baseline, 61.5% of patients were men, and 62.7% of patients were aged 50 years or older. The median follow-up period was 15 months (IQR 13 to 17 months). Researchers found that the RFS was longer in the pembrolizumab arm compared with the placebo arm (HR 0.56, 98.4% CI 0.43 to 0.74), consistent with the reported main analysis. The incidence of grade 1 or higher irAEs at both 3 months and 15 months was greater in the pembrolizumab group than in the placebo group (3 months: pembrolizumab 19.4%, 95% CI 16.1% to 23.0%; placebo 4.0%, 95% CI 2.5% to 6.0%, 15 months: pembrolizumab 37.4%, 95% CI 33.2% to 41.6%; placebo 9.0%, 95% CI 6.7% to 11.7%; HR 4.95, 95% CI 3.58 to 6.85, p<0.001). The most common irAEs were endocrine disorders and vitiligo. Of those who experienced an irAE, 17.3% patients in the pembrolizumab arm and 13.3% in the placebo arms discontinued treatment due to an irAE. The occurrence of an irAE was associated with a longer RFS in the pembrolizumab arm (HR 0.61, 95% CI 0.39 to 0.95, p=0.03) but not in the placebo arm (HR 1.37, 95% CI 0.82 to 2.29, p=0.21). Moreover, compared with the placebo arm, the reduction in the hazard of recurrence or death in the pembrolizumab arm was greater after an irAE than without or before an irAE (HR 0.37, 95% CI 0.24 to 0.57 vs. HR 0.61, 95% CI 0.49 to 0.77, respectively, p=0.03). Finally, systemic steroid use for irAEs was associated with a higher estimated HR than no steroid use (HR 0.50, 95% CI 0.23 to 1.07 vs. HR 0.34, 95% CI 0.21 to 0.56, respectively). In summary, this study suggests that irAEs are associated with a longer recurrence-free survival in patients with stage III melanoma treated with pembrolizumab.

Click to read the study in JAMA Oncology

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

 

Tags: adverse effectsmelanomaPembrolizumabsteroids
Previous Post

Long-Term Outcomes Associated With Total Arterial Revascularization vs Non-Total Arterial Revascularization

Next Post

Predicting Death By Suicide Following An Emergency Department Visit For Parasuicide With Administrative Health Care System Data and Machine Learning

RelatedReports

#StudyGraphics: Atezolizumab in combination with vemurafenib and cobimetinib improve progression-free survival in patients with BRAFV600-advanced melanoma
StudyGraphics

#StudyGraphics: Atezolizumab in combination with vemurafenib and cobimetinib improve progression-free survival in patients with BRAFV600-advanced melanoma

March 15, 2023
#VisualAbstract: Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma
StudyGraphics

#VisualAbstract: Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma

March 9, 2023
Adding sargramostim to ipilimumab may improve survival in advanced melanoma
Oncology

Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma

March 6, 2023
#VisualAbstract: Adjuvant pembrolizumab improves distant  metastasis-free survival in stage IIB-C melanoma
StudyGraphics

#VisualAbstract: Adjuvant pembrolizumab improves distant metastasis-free survival in stage IIB-C melanoma

February 13, 2023
Next Post
Concussion or mild traumatic brain injury linked with increased risk of suicide

Predicting Death By Suicide Following An Emergency Department Visit For Parasuicide With Administrative Health Care System Data and Machine Learning

#VisualAbstract: Safety and Efficacy of Femoral Access vs Radial Access in ST-Segment Elevation Myocardial Infarction

#VisualAbstract: Safety and Efficacy of Femoral Access vs Radial Access in ST-Segment Elevation Myocardial Infarction

Myeloperoxidase upregulation in epileptogenesis seen on molecular imaging

Associations Between Life-Course-Persistent Antisocial Behaviour and Brain Structure In a Population-Representative Longitudinal Birth Cohort

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Synergistic interaction between risk burden and genetics for atrial fibrillation development
  • Nivolumab plus ipilimumab does not improve survival in post-nephrectomy patients with renal cell carcinoma
  • Specific histopathologic renal lesions may be associated with increased risk of cardiovascular disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options